Vor-Wordmark-RGB-FullColor-070920.png
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
June 09, 2023 07:30 ET | Vor Biopharma
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust enrollment; additional data...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in the Goldman Sachs Healthcare Conference
June 05, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will present and host in-person 1x1 investor meetings at the Goldman...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
May 11, 2023 16:05 ET | Vor Biopharma
VBP101 clinical data update planned at European Hematology Association (EHA) 2023VCAR33ALLO IND submission on-track for 1H 2023 CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq:...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
April 18, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
March 23, 2023 16:01 ET | Vor Biopharma
Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplantAdditional trem-cel data expected by year-end 2023; VCAR33ALLO...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
February 21, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
February 16, 2023 12:00 ET | Vor Biopharma
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of MylotargMylotarg treatment enriched CD33-negative donor hematopoiesisSecond patient successfully received...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
January 19, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
December 07, 2022 07:45 ET | Vor Biopharma
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private...